Elicio Therapeutics, Inc. Cash Flow Statement
ELTX|2 years of annual SEC 10-K data (FY2021-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Elicio Therapeutics, Inc. used $53M in operating cash flow and negative free cash flow of $53M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.36 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 |
|---|---|---|
| Net Income | -$54.6M | -$80.1M |
| Depreciation & Amortization | $91.0K | $98.0K |
| Operating Cash Flow | -$52.6M | -$22.9M |
| Capital Expenditures | $382.0K | $41.0K |
| Free Cash Flow | -$53.0M | -$22.9M |
| FCF Margin | -187.3% | -796.1% |